BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Rheumatoid arthritis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for rheumatoid arthritis: 212 (111 sponsors; 27 newly posted in the last 180 days, 8 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 9.4, rank 74 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 7, Phase 1 51, Phase 2 41, Phase 3 18, Phase 4 0, N/A 95.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 8 | NA 1, P3 4, P1 2, P2 1 | 2 | 1 |
| Novartis Pharmaceuticals NVS | 9 | P2 3, P3 3, NA 1, P1 2 | 3 | 1 |
| Amgen AMGN | 3 | P2 1, P3 2 | 0 | 0 |
| AbbVie ABBV | 6 | P2 2, P1 2, NA 1, P3 1 | 2 | 1 |
| SetPoint Medical Corporation | 3 | P3 1, NA 2 | 0 | 1 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | 2 | P2 1, P3 1 | 1 | 1 |
| Beijing VDJBio Co., LTD. | 1 | P3 1 | 0 | 0 |
| Biocad | 1 | P3 1 | 0 | 0 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 1 |
| Jiankuan (Suzhou) Biotechnology Company Limited new entrant | 1 | P3 1 | 1 | 1 |
| Swedish Orphan Biovitrum | 1 | P3 1 | 0 | 0 |
| Vor Biopharma VOR | 1 | P3 1 | 0 | 0 |
| Zimmer Biomet ZBH | 24 | NA 24 | 0 | 6 |
| MicroPort Orthopedics Inc. | 10 | NA 10 | 0 | 0 |
| Medacta International SA | 9 | NA 9 | 0 | 0 |
| Aesculap AG | 5 | NA 5 | 0 | 0 |
| AstraZeneca AZN | 4 | P2 2, P1 2 | 0 | 1 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 4 | P1 3, NA 1 | 0 | 2 |
| Stryker Trauma and Extremities SYK | 4 | NA 4 | 0 | 0 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 3 | P2 2, P1 1 | 0 | 0 |
| Exactech | 3 | NA 3 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 3 | P2 2, P1 1 | 1 | 0 |
| Candid Therapeutics | 2 | P1 2 | 1 | 0 |
| Cullinan Therapeutics Inc. CGEM | 2 | P1 2 | 0 | 0 |
| Eli Lilly and Company LLY | 2 | P1 2 | 0 | 0 |
New-entrant sponsors: Jiankuan (Suzhou) Biotechnology Company Limited.
Recently stopped trials
- NCT04313725 Tangible Science - terminated: Slow enrollment and difficulty getting patients to complete the study visits (significantly impacted by COVID-19 pandemic) Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
- NCT06544642 Astellas Pharma Global Development, Inc. - terminated: Company's strategic decision A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
- NCT07706868 Swedish Orphan Biovitrum - withdrawn: Business decision An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (S
- NCT03247023 Smith & Nephew, Inc. - terminated: Sponsor decision not related to safety Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
- NCT06859294 Eli Lilly and Company - terminated: The interim analysis data failed to demonstrate the intended treatment effect. A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
- NCT05002959 Zimmer Biomet - terminated: Termination of PMCF study due to product discontinuation (commercial reasons) TESS V3 Modular Total Shoulder System PMCF
- NCT07100938 BeiGene - terminated: Sponsor has concluded that patients are unlikely to derive sufficient benefit from treatment with BGB-45035 to support continuation of the c A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheum
- NCT06031415 Gilead Sciences - terminated: Study terminated due to lack of efficacy. Study of GS-0272 in Participants With Rheumatoid Arthritis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Toll Biotech Co. Ltd. (Beijing) | NCT07408024 Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis (RA) | recruiting | 24 |
| 2026-12-31 est. | P3 | Hangzhou Highlightll Pharmaceutical Co., Ltd | NCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | active not recruiting | 350 |
| 2027-01-15 est. | P2 | XBiotech, Inc. XBIT | NCT06590090 Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Rheumatoid Arthritis | not yet recruiting | 108 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | recruiting | 180 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Spyre Therapeutics, Inc. SYRE | NCT07148414 A Study of SPY072 in Rheumatic Disease | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Jo | active not recruiting | 285 |
| 2026-09-07 | P2 | Merck Sharp & Dohme LLC MRK | NCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Arthritis, Rheumatoid | active not recruiting | 185 |
| 2026-07-15 | P3 | AbbVie ABBV | NCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Se | Rheumatoid Arthritis | completed | 487 |
| 2026-07-02 | P2 | Citryll BV | NCT06567470 A Study With CIT-013 in RA Patients | Rheumatoid Arthritis | completed | 96 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "rheumatoid arthritis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.